Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

COVID-19 (SARS-CoV-2) mRNA vaccination does not affect basal sex hormone levels (follicle-stimulating hormone, luteinizing hormone, estradiol) in reproductive-age women

  • Haeng Jun Jeon (CHA Fertility Center Gangnam, CHA University School of Medicine) ;
  • Woo Sik Lee (CHA Fertility Center Gangnam, CHA University School of Medicine) ;
  • Ji Eun Park (CHA Fertility Center Gangnam, CHA University School of Medicine) ;
  • Ji Young Hwang (CHA Fertility Center Gangnam, CHA University School of Medicine) ;
  • Ji Won Kim (CHA Fertility Center Gangnam, CHA University School of Medicine)
  • Received : 2023.04.28
  • Accepted : 2023.11.18
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: People vaccinated with the coronavirus disease 2019 (COVID-19) (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) mRNA vaccine have reported experiencing various adverse effects. For instance, reproductive-age women have presented with complaints of abnormal uterine bleeding or menstrual cycle changes. We speculated that differences in basal sex hormone levels before and after vaccination may be present in women who experienced irregular bleeding or menstrual cycle changes; thus, this study aimed to investigate the differences in basal sex hormone levels of women before and after two doses of SARS-CoV-2 mRNA vaccination. Methods: This retrospective study included patients who received SARS-CoV-2 mRNA vaccines between January 2021 and February 2022 at a single center. In an outpatient setting, patients were queried regarding their menstrual cycle, the date of SARS-CoV-2 mRNA vaccination, vaccination type, and vaccination side effects. Differences in basal hormone levels (menstrual cycle days 2-3, follicle-stimulating hormone [FSH], luteinizing hormone [LH], and estradiol) before and after vaccination were compared. Results: Among the 326 patients, patients with no laboratory records of the hormones were excluded. The median time interval between SARS-CoV-2 mRNA vaccination and the laboratory test day was 79 days (interquartile range, 44 to 127). A comparative analysis of these hormones before and after vaccination revealed no significant differences. Subgroup analyses based on age and reported adverse events also found no statistically significant differences. Conclusion: This study showed no significant differences in basal hormone levels (FSH, LH, and estradiol) before and after SARS-CoV-2 mRNA vaccination.

Keywords

Acknowledgement

The authors would like to thank all participants and staff at CHA Fertility Center.

References

  1. World Health Organization. Global Covid-19 vaccination strategy in a changing world: July 2022 updated [Internet]. WHO; 2022 [cited 2023 Dec 6]. Available from: https://www.who.int/docs/default-source/coronaviruse/global-covid-19-vaccination-strategy-in-a-changing-world---july-2022-update.pdf 
  2. Goel H, Gupta I, Mourya M, Gill S, Chopra A, Ranjan A, et al. A systematic review of clinical and laboratory parameters of 3,000 COVID-19 cases. Obstet Gynecol Sci 2021;64:174-89. 
  3. Akbar MIA, Gumilar KE, Andriya R, Wardhana MP, Mulawardhana P, Anas JY, et al. Clinical manifestations and pregnancy outcomes of COVID-19 in Indonesian referral hospital in central pandemic area. Obstet Gynecol Sci 2022;65:29-36. 
  4. U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine [Internet]. FDA; 2023 [cited 2023 Dec 6]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines 
  5. Bentov Y, Beharier O, Moav-Zafrir A, Kabessa M, Godin M, Greenfield CS, et al. Ovarian follicular function is not altered by SARS-CoV-2 infection or BNT162b2 mRNA COVID-19 vaccination. Hum Reprod 2021;36:2506-13. 
  6. Amanzio M, Mitsikostas DD, Giovannelli F, Bartoli M, Cipriani GE, Brown WA. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: a systematic review. Lancet Reg Health Eur 2022;12:100253. 
  7. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. JAMA 2021;326:1210-2. 
  8. Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-Ronen Y, et al. The coding capacity of SARS-CoV-2. Nature 2021;589:125-30. 
  9. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2022;23:3-20. 
  10. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21:939-49. 
  11. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021;325:780-1. 
  12. Gadi SRV, Brunker PA, Al-Samkari H, Sykes DB, Saff RR, Lo J, et al. Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccine. Transfusion 2021;61:3267-71. 
  13. Park J, Park MS, Kim HJ, Song TJ. Association of cerebral venous thrombosis with mRNA COVID-19 vaccines: a disproportionality analysis of the World Health Organization Pharmacovigilance Database. Vaccines (Basel) 2022;10:799. 
  14. Ahn KH, Kim HI, Lee KS, Heo JS, Kim HY, Cho GJ, et al. COVID-19 and vaccination during pregnancy: a systematic analysis using Korea National Health Insurance claims data. Obstet Gynecol Sci 2022;65:487-501. 
  15. Korea Disease Control and Prevention Agency. COVID-19 vaccination in Korea [Internet]. KDCA; 2023 [cited 2023 Dec 6]. Available from: https://ncv.kdca.go.kr 
  16. Alvergne A, Woon EV, Male V. Effect of COVID-19 vaccination on the timing and flow of menstrual periods in two cohorts. Front Reprod Health 2022;4:952976. 
  17. Chen F, Zhu S, Dai Z, Hao L, Luan C, Guo Q, et al. Effects of COVID-19 and mRNA vaccines on human fertility. Hum Reprod 2021;37:5-13. 
  18. Edelman A, Boniface ER, Benhar E, Han L, Matteson KA, Favaro C, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. Obstet Gynecol 2022;139:481-9. 
  19. Hallberg E, Sundstrom A, Larsson M, Arthurson V, Ljung R. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. Obstet Gynecol 2022;139:940-1. 
  20. Horowitz E, Mizrachi Y, Ganer Herman H, Oz Marcuschamer E, Shalev A, Farhi J, et al. The effect of SARS-CoV-2 mRNA vaccination on AMH concentrations in infertile women. Reprod Biomed Online 2022;45:779-84. 
  21. Lee KM, Junkins EJ, Luo C, Fatima UA, Cox ML, Clancy KB. Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. Sci Adv 2022;8:eabm 7201. 
  22. Mohr-Sasson A, Haas J, Abuhasira S, Sivan M, Doitch Amdurski H, Dadon T, et al. The effect of Covid-19 mRNA vaccine on serum anti-Mullerian hormone levels. Hum Reprod 2022;37:534-41. 
  23. University of Missouri Health Care. Does the COVID-19 vaccine affect fertility? Here's what the experts say [Internet]. MU Health Care; 2023 [cited 2023 Dec 6]. Available from: https://livehealthy.muhealth.org/stories/does-covid-19-vaccine-affect-fertility-heres-what-experts-say 
  24. Male V. Menstrual changes after COVID-19 vaccination. BMJ 2021;374:n2211. 
  25. Messinis IE. Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod Update 2006;12:557-71. 
  26. Smotrich DB, Widra EA, Gindoff PR, Levy MJ, Hall JL, Stillman RJ. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril 1995;64:1136-40. 
  27. Abdalla H, Thum MY. An elevated basal FSH reflects a quantitative rather than qualitative decline of the ovarian reserve. Hum Reprod 2004;19:893-8. 
  28. Jenkins JM, Anthony FW, Lee A, Masson GM, Thomas E. Persistent elevation of serum oestradiol levels by functional ovarian cysts despite effective pituitary desensitization with GnRH agonists. Clin Endocrinol (Oxf) 1994;40:357-9. 
  29. Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am 2008;35:219-34. 
  30. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol 2013;122:176-85. 
  31. Munro MG, Critchley HO, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet 2018;143:393-408. 
  32. Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. In: Feingold KR, Anawalt B, Blackman MR, editors. Endotext. MDText.com Inc.; 2000 [cited 2023 Dec 6]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279054 
  33. Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause 2011;18:408-11. 
  34. Schatz F, Guzeloglu-Kayisli O, Arlier S, Kayisli UA, Lockwood CJ. The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Hum Reprod Update 2016;22:497-515. 
  35. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2020;114:1151-7.